The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Pfizer’s rheumatoid arthritis (RA) candidate tofacitinib could see its review date pushed back thanks to an FDA request for an additional analysis. The company plans to provide the analysis of existing data in early August, ahead of the drug’s originally scheduled Aug. 21 action goal date, CEO Ian Read said Tuesday during the company’s second-quarter earnings call. Any delay could be a small positive for Abbott’s Humira (adalimumab), Wells Fargo analyst Larry Biegelsen noted. Every $100 million in tofacitinib sales would result in about $25 million in lost Humira sales, Biegelsen estimates. Washington Drug Letter